• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cassava Sciences Inc (NQ: SAVA )

    26.21 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,113
    Open 26.21
    Bid (Size) 26.00 (36)
    Ask (Size) 26.33 (1)
    Prev. Close 26.21
    Today's Range 26.21 - 26.21
    52wk Range 8.790 - 42.20
    Shares Outstanding 41,969,994
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
    Conference call and webcast to begin at 8:30 AM ET 
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Analysts Believe Cassava Sciences Now Has 300% Upside From Here
    Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
    Via MarketBeat
    Topics Fraud Lawsuit
    Exposures Criminal Legal

    Performance

    YTD
    +16.90%
    +16.90%
    1 Month
    -3.21%
    -3.21%
    3 Month
    -25.29%
    -25.29%
    6 Month
    +21.79%
    +21.79%
    1 Year
    +22.59%
    +22.59%

    More News

    Read More
    How Is The Market Feeling About Cassava Sciences?
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
    Via Benzinga
    Cassava Sciences Unusual Options Activity
    Via Benzinga
    Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
    Via Benzinga
    Exposures Fossil Fuels
    What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
    Via Benzinga
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Why Cassava Sciences Stock Dived by Almost 11% Today
    Via The Motley Fool
    Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
    Via Benzinga
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Cassava Sciences Resolves SEC Investigation
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
    Via Benzinga
    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Cassava Sciences Names Rick Barry as Chief Executive Officer
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    9 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
    Via MarketBeat
    SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.